Compare RAND & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAND | HOWL |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 30.7M |
| IPO Year | 1996 | 2021 |
| Metric | RAND | HOWL |
|---|---|---|
| Price | $11.25 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 4.5K | ★ 347.2K |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $0.53 |
| 52 Week High | $21.30 | $2.23 |
| Indicator | RAND | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 54.23 |
| Support Level | $10.31 | $0.56 |
| Resistance Level | $12.50 | $0.80 |
| Average True Range (ATR) | 0.57 | 0.08 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 82.15 | 62.56 |
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.